CNS pharmaceutical developer Vallon Pharmaceuticals files for a $17 million IPO

Vallon Pharmaceuticals, a biopharmaceutical company developing abuse-deterrent prescription drugs for CNS disorders, filed on Friday with the SEC to raise up to $17 million in an initial public offering.

The company's clinical-stage product currently under development is Abuse-Deterrent Amphetamine Immediate-Release, or ADAIR, a proprietary, abuse-deterrent oral formulation of immediate-release (short-acting) dextroamphetamine for the treatment of attention-deficit/hyperactivity disorder, or ADHD, and narcolepsy. ADAIR has completed a Phase 1 pivotal bioequivalence study and a Phase 1 food effect study.

The Philadelphia, PA-based company was founded in 2018. The company has not selected a listing exchange or ticker yet (RC ticker: VALL.RC). Vallon Pharmaceuticals filed confidentially on September 11, 2020. ThinkEquity is the sole bookrunner on the deal. No pricing terms were disclosed.

The article CNS pharmaceutical developer Vallon Pharmaceuticals files for a $17 million IPO originally appeared on IPO investment manager Renaissance Capital's web site renaissancecapital.com.

Investment Disclosure: The information and opinions expressed herein were prepared by Renaissance Capital's research analysts and do not constitute an offer to buy or sell any security. Renaissance Capital's Renaissance IPO ETF (symbol: IPO), Renaissance International ETF (symbol: IPOS), or separately managed institutional accounts may have investments in securities of companies mentioned.

The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.

Latest IPOs Videos

Nordic Listings End of Year Sizzle Reel

Jan 18, 2022

Renaissance Capital

Renaissance Capital is the global leader in providing pre-IPO institutional research and management of IPO-focused investment products.

Learn More